Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)
Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)
Observational, multicentre, epidemiological study to determine the HRQOL of patients with
 epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse
 Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients
 receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients
 receiving combination therapy.
Inclusion Criteria:

 -  Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months

 Exclusion Criteria:

 -  Symptomatic epilepsy due to malignant brain tumour or progressive brain disease.

 -  Confirmed diagnosis of a concomitant chronic disease